CP
AGIO icon

Caligan Partners’s Agios Pharmaceuticals AGIO Stock Holding History

Caligan Partners’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-975,000
Closed -$39.1M – 26
2025
Q3 		$39.1M Buy
+975,000
New +$36.7M 5.13% 7

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Caligan Partners's AGIO Position: Q4 2025 in Review

Caligan Partners sold out of Agios Pharmaceuticals (AGIO) in Q4 2025, closing a stake of 1,131,205 shares — an estimated $39.7M sold.

Caligan Partners first reported a position in AGIO in Q4 2022 and held it in 12 quarters. The position peaked at $45.4M in Q3 2025. 237 funds tracked by Wall St. Rank hold AGIO as of Q4 2025.

  • Caligan Partners reported no remaining Agios Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Caligan Partners sold 1,131,205 Agios Pharmaceuticals shares in Q4 2025, an estimated $39.7M.
  • Caligan Partners first reported a position in Agios Pharmaceuticals in Q4 2022 and held it in 12 quarters.
  • Caligan Partners's Agios Pharmaceuticals position peaked at $45.4M in Q3 2025.
  • 237 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2025.

Based on Caligan Partners's 13F filing for Q4 2025, filed 17 Feb 2026.